RecruitingPhase 1NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Incyte Medical MonitorIncyte Corporation
- Intervention
- INCA036978(drug)
- Enrollment
- 218 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2030
Study locations (30)
- University of Alabama At Birmingham, Birmingham, Alabama, United States
- City of Hope-Lennar Foundation Cancer Center, Irvine, California, United States
- Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Medical Hematology & Oncology, Los Angeles, California, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- University of Miami, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- John Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Mount Sinai School of Medicine, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07441694 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami
- RECRUITINGNCT06480591Evaluation of the Pathobiology of CALR-mutated MPN CellsWake Forest University Health Sciences
- RECRUITINGPHASE3NCT06740916Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin ResistanceSiriraj Hospital